Legend Biotech Corporation (LEGN) — Financial statements
Income statement, balance sheet, and cash flow for Legend Biotech Corporation — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,029↑64.0% | 627↑120.0% | 285↑143.7% | 117↑70.0% | 69 | |
| Cost of Revenue | 408↑74.0% | 235↑62.7% | 144↑120.6% | 65 | 0.00 | |
| Gross Profit | 621↑58.1% | 393↑178.6% | 141↑172.9% | 52↓25.0% | 69 | |
| Operating Expenses | ||||||
| R&D Expenses | 415↑0.3% | 414↑8.2% | 382↑13.9% | 336↑7.1% | 313 | |
| General & Administrative Expenses | 136↓0.7% | 137↑28.1% | 107↑32.4% | 81↑71.7% | 47 | |
| Selling & Marketing Expenses | 206↑39.5% | 147↑56.6% | 94↑0.8% | 93↓8.9% | 103 | |
| SG&A Expenses | 342↑20.2% | 284↑41.5% | 201↑15.4% | 174↑16.4% | 150 | |
| Other Expenses | 1↑152.5% | -2↑30.2% | -3↓12.2% | -2↓40.2% | -2 | |
| Operating Expenses | 757↑8.8% | 696↑19.9% | 580↑14.4% | 507↑10.0% | 461 | |
| Total Costs & Expenses | 1,165↑25.2% | 930↑28.4% | 725↑26.5% | 573↑24.2% | 461 | |
| Operating Results | ||||||
| Operating Income | -137↑55.0% | -303↑31.0% | -439↑3.5% | -456↓16.1% | -392 | |
| Depreciation & Amortization | 29↑23.7% | 23↑14.2% | 20↑11.2% | 18↑32.2% | 14 | |
| EBITDA | -232↓105.3% | -113↑76.3% | -478↓14.7% | -417↓6.2% | -392 | |
| EBIT | -261↓91.3% | -137↑72.6% | -498↓14.6% | -435↓7.0% | -406 | |
| Interest & Other Income | ||||||
| Net Interest Income | 19↓52.8% | 40↑21.1% | 33↑1350.7% | -3↓3781.7% | 0.07 | |
| Interest Income | 40↓34.5% | 61↑12.3% | 54↑565.9% | 8↑742.6% | 0.97 | |
| Interest Expense | 21↓1.0% | 22↓0.8% | 22↑101.9% | 11↑1099.6% | 0.90 | |
| Non-Operating Income | 125↑174.8% | -167↓383.4% | 59↑384.4% | -21↓247.7% | 14 | |
| Other Income / Expenses | -146↓200.7% | 145↑280.0% | -81↓914.8% | 10↑166.4% | -15 | |
| Income Before Tax | -283↓78.7% | -158↑69.6% | -520↓16.7% | -446↓9.5% | -407 | |
| Income Tax Expense | 14↓24.8% | 19↑1113.6% | -2↓398.2% | 0.63↑117.3% | -4 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -297↓67.7% | -177↑65.8% | -518↓16.1% | -446↓10.6% | -404 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -297↓67.7% | -177↑65.8% | -518↓16.1% | -446↓10.6% | -404 | |
| Bottom-Line Net Income | -297↓67.7% | -177↑65.8% | -518↓16.1% | -446↓10.6% | -404 | |
| EPS (Basic) | -1.60↓64.9% | -0.97↑67.0% | -2.94↓4.6% | -2.81↓2.6% | -2.74 | |
| EPS (Diluted) | -1.60↓64.9% | -0.97↑67.0% | -2.94↓4.6% | -2.81↓2.6% | -2.74 | |
| Weighted Average Shares | 184↑0.8% | 183↑3.8% | 176↑10.7% | 159↑12.9% | 141 | |
| Weighted Average Diluted Shares | 184↑0.8% | 183↑3.8% | 176↑10.7% | 159↑12.9% | 141 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.